Thursday - December 11, 2025

Category Archives: Pharmaceuticals & Biotech

Aplastic Anemia Clinical Trial Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Aplastic Anemia- Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Aplastic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment … Continue reading →

Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Hereditary Angioedema Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Hthe ereditary Angioedema pipeline landscape. It covers the Hereditary Angioedema pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Systemic Mastocytosis Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight

DelveInsight’s, “Systemic Mastocytosis Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the Systemic Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Immune Thrombocytopenia Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Immune Thrombocytopenia Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Immune Thrombocytopenia pipeline landscape. It covers the Immune Thrombocytopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

HER2-Negative Breast Cancer Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also … Continue reading →

Iodine Market growing at 5.48% CAGR Forecast 2025-2030, Top Key Players – Algorta Norte, Cosayach, Iofina plc | Mordor Intelligence

Iodine Market According to Mordor Intelligence, Iodine Market Size, Share & Trends Forecast 2025-2030,” offers an in-depth analysis of the regional dynamics shaping this rapidly evolving industry. The global iodine market volume stands at 42.87 kilotons, supported by consistent use … Continue reading →

Triple Negative Breast Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Akeso Biopharma, ProLynx, ModernaTX, OncoTherapy Science, Phoenix Molecular Designs

The Key Triple Negative Breast Cancer Companies in the market include – Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui … Continue reading →

HER2+ Gastric Cancer Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Pfizer, Bayer, Merck, Daiichi Sankyo and AstraZeneca, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology

The Key HER2+ Gastric Cancer Companies in the market include – Merck, Daiichi Sankyo and AstraZeneca, Jazz Pharmaceuticals, BeiGene, and Zymeworks, Shanghai Henlius Biotech and AbClon, AstraZeneca, ALX Oncology, Pfizer, Bayer, Artiva Biotherapeutics and GC Cell, KLUS Pharma, Shanghai Miracogen, … Continue reading →

GLP-1 Agonists Market to Reach USD 170.75 Billion by 2033 Driven by Manufacturing Expansion, Indication Growth, and Rising Metabolic Disease Burden

The market for GLP-1 agonists is highly consolidated, with key players strategizing to capture the market. Prominent players in the GLP-1 agonists market are Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players. Browse 400 market data … Continue reading →

In Vitro Diagnostics Market: Rising to USD 157.63 Billion by 2030 Amid Personalized Medicine and Technological Innovation

In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030 Some of the prominent players operating in the market … Continue reading →